drugset / Trial / NCT00970528

Glucose Reduction by Early Acarbose Treatment in Basal Insulin

NCT00970528

Phase 4 Completed 124 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetic patients whose blood glucose levels were inadequately controlled with insulin glargine alone or in combination with metformin.

Timeline

Start
2009-11
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Acarbose Unknown 100 mg
Comparator Voglibose Small molecule 0.3 mg